These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 4015739)
1. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate]. Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739 [TBL] [Abstract][Full Text] [Related]
2. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations]. Geigenberger A; Degen J; Maier-Lenz H Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839 [TBL] [Abstract][Full Text] [Related]
3. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. Rietbrock N; Knoll J; Merz PG; Menke G Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327 [TBL] [Abstract][Full Text] [Related]
4. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789 [TBL] [Abstract][Full Text] [Related]
5. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657 [TBL] [Abstract][Full Text] [Related]
6. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135 [TBL] [Abstract][Full Text] [Related]
7. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man. Johnson KI; Gladigau V; Schnelle K Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234 [TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate. Laufen H; Leitold M; Wildfeuer A Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973 [TBL] [Abstract][Full Text] [Related]
9. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. Hutt V; Theodor R; Pabst G; Lutz D; Bonn R; Fritschi E Arzneimittelforschung; 1993 Aug; 43(8):842-6. PubMed ID: 8216439 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of 14C-isosorbide dinitrate after administration in various sustained-release formulations]. Chasseaud LF; Taylor T; Major RM; Taylor IW; Luckow V; Darragh A; Lambe RF Arzneimittelforschung; 1983; 33(9):1298-301. PubMed ID: 6685511 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768 [TBL] [Abstract][Full Text] [Related]
12. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers]. Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006 [TBL] [Abstract][Full Text] [Related]
13. [Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate]. Heidemann R; Gracien E; Menke G; Rietbrock N Dtsch Med Wochenschr; 1987 May; 112(18):719-22. PubMed ID: 3569063 [TBL] [Abstract][Full Text] [Related]
14. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard). Neugebauer G; Akpan W; Stemmle B; Jaeger H; Mosberg H; Lutz D Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):34-8. PubMed ID: 2744904 [TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063 [TBL] [Abstract][Full Text] [Related]
16. [Dose-dependent serum concentration of ISDN and its metabolites following administration of ISDN-retard. Studies under steady-state conditions]. Loew D; Deuster U; Burkhardt H; Rietbrock N Dtsch Med Wochenschr; 1986 Nov; 111(48):1834-7. PubMed ID: 3536397 [TBL] [Abstract][Full Text] [Related]
18. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. Menke G; Schnellhammer R; Rietbrock N Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. Skutta T; Böttcher B; Brandt L Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738 [TBL] [Abstract][Full Text] [Related]
20. Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations. Galeazzi RL; Platzer R; Reutemann G Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):387-93. PubMed ID: 6629543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]